Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company focused on delivering therapeutics through effective oral delivery, announced today that it has received revised regulatory guidance for LPCN ...

APAC is expected to grow the fastest in the coming years. The global human microbiome market is projected to grow from $1.07b ...

Colorado's cannabis testing loopholes have led to consumers being deceived about the safety of the products they buy, with ...

In November, virologist Beata Halassy announced to the world that she had cured her own breast cancer using a treatment ...

Bushra Sumra's career highlights the profound impact that expertise in clinical research and regulatory compliance can have on advancing treatments for rare diseases.

An ad airing Super Bowl Sunday features “America’s deadliest epidemic,” obesity, and what can be done about it with the use ...

It isn’t just artificial intelligence. Chinese biotech companies are now developing drugs faster and cheaper than their U.S.

The U.S. Food and Drug Administration (FDA) issued a final guidance for industry titled Action Levels for Lead in Processed Food Intended for ...

President Donald Trump is facing pressure from U.S. hospitals and generic drugmakers to exempt medical goods from his new ...

Debra Patt, MD, PhD, MBA, MPH, warns that prior authorization barriers are delaying critical cancer treatments and urges a ...

The platform enables direct, unbiased genome-wide identification and quantification of the exact position of double strand DNA breaks in edited cells.

Kuro Oncology and partner Kyowa Kirin are on track for an NDA submission for ziftomenib in the second quarter of this year.